RVL Pharmaceuticals plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- RVL Pharmaceuticals plc operates as a specialty pharmaceutical company focused on the development and commercialization of products targeting underserved patient populations in the ocular and medical aesthetics therapeutic areas. The company offers UPNEEQ (oxymetazoline hydrochloride ophthalmic solution, 0.1%), the first FDA-approved non-surgical treatment for acquired blepharoptosis, or droopy eyelid, in adults; it previously marketed products such as Lorzone and M-72 for neurology and women's health prior to strategic streamlining. Founded in 1986 and headquartered at 400 Crossing Boulevard in Bridgewater, New Jersey, RVL conducts operations primarily in the United States, with additional presence in Argentina and Hungary. In late 2023, certain U.S. subsidiaries completed a prepackaged reorganization and financial restructuring, converting debt held by Athyrium Capital Management into equity ownership and securing incremental financing to support growth and operations focused on UPNEEQ; public equity was cancelled as part of the wind-down of non-core entities. Recent commercial investments drove a 22% year-over-year revenue increase for UPNEEQ in Q3 2025 versus Q3 2024, alongside leadership appointments to accelerate expansion into a $2.5 billion total addressable market; the company rebranded from Osmotica Pharmaceuticals plc in January 2022.
RVL Completes Financial Restructuring
Why Is RVL Pharmaceuticals (RVLP) Stock Up 40% Today?
RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries
Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
RVL Pharmaceuticals: A First 'Look'
RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Call Transcript
RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates
RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q2 2022 Results - Earnings Call Transcript
RVL Pharmaceuticals plc to Present at Upcoming Conferences
RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q1 2022 Results - Earnings Call Transcript
RVL Pharmaceuticals PLC (RVLP) Reports Q1 Loss, Tops Revenue Estimates
RVL Pharmaceuticals plc (RVLP) CEO Brian Markison on Q4 2021 Results - Earnings Call Transcript
RVL Pharmaceuticals PLC (RVLP) Reports Q4 Loss, Misses Revenue Estimates